Emergent BioSolutions | EBS - Cash And Equivalent


Emergent BioSolutions reported $111.7M in Cash and Equivalent for its fiscal quarter ending in December of 2023.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 851.46M 31.77M Mar/2026
Akebia Therapeutics USD 162.64M 22.2M Mar/2026
ALKERMES USD 351.55M 37.02M Mar/2026
Alnylam Pharmaceuticals USD 1.71B 53.53M Mar/2026
Amarin USD 131.06M 3.6M Mar/2026
ANI Pharmaceuticals USD 311.18M 25.59M Mar/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Coherus Biosciences USD 88.88M 14.47M Dec/2025
Emergent BioSolutions USD 111.7M 23.9M Dec/2023
Exelixis USD 226.15M 256.34M Mar/2026
Glaxosmithkline GBP 3.44B 146M Mar/2026
Heron Therapeutics USD 26.12M 2.53M Mar/2026
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
Ironwood Pharmaceuticals USD 220.47M 5.01M Mar/2026
Lexicon Pharmaceuticals USD 38.09M 3.76M Mar/2026
Lonza CHF 719M 188M Dec/2025
Merck USD 5.33B 9.24B Mar/2026
Moderna USD 1.91B 687M Mar/2026
Myriad Genetics USD 124.4M 25.2M Mar/2026
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Neurocrine Biosciences USD 266.5M 446.5M Mar/2026
Pacira USD 144.31M 14.24M Mar/2026
Pfizer USD 1.7B 561M Mar/2026
PTC Therapeutics USD 833.99M 150.66M Mar/2026
Sanofi EUR 7.66B 1.25B Dec/2025
Sarepta Therapeutics USD 464.45M 336.83M Mar/2026
United Therapeutics USD 1.28B 277.4M Mar/2026
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025
Xoma USD 143.9M 7.68M Jun/2024